Daily, Tue 10 Nov: A Chinese firm comes off a Pentagon list. Is the risk gone?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
This episode covers the US Defense Department's removal of WuXi AppTec from its 1260H list and what it does not settle, two Chinese antibody–drug conjugates in EGFR-mutated lung cancer from Biokin and Hengrui, and Vir's hepatitis delta result with the China angle through Brii Biosciences. Beyond biotech: Singapore's SG-INSIGHT genome sequencing, a two-step chemogenetic approach to drug-resistant epilepsy from Beijing, and a new FDA eye-risk warning for GLP-1 drugs.
Full transcript and all sources for this episode
Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Neither Basil nor Ning holds investments in any company mentioned.
Chapters
0:00 Intro and AI-voice disclosure
0:54 WuXi AppTec and the Pentagon list
2:33 Two Chinese ADCs in EGFR lung cancer
5:33 Hepatitis: Vir and Brii's shared drug
7:16 Beyond: Singapore's SG-INSIGHT genomes
8:19 Beyond: a chemogenetic switch for epilepsy
9:23 Beyond: FDA GLP-1 eye warning
10:06 What to watch and sign-off
Key sources: Federal Register: WuXi AppTec 1260H removal · BMS: PANKU-Lung01 (company press release) · ASCO Post: HERON-Lung01 · Vir: ECLIPSE 1 (company press release) · FDA: GLP-1 NAION safety communication (all sources on the episode page)
Weekly LinkedIn newsletter
Also listen on: Apple Podcasts · Amazon Music · YouTube